Mi Nk Therapeutics
Biotechnology, 3 Forbes Rd, Lexington, , 2421, Massachusetts, United States, 11-50 Employees
Phone Number: 21********
Who is MINK THERAPEUTICS
We are a clinical stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapi...
Read More
-
Headquarters: 3 Forbes Rd, Lexington, Massachusetts, 2421, United States
-
Date Founded: 2017
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 325414 |
Show More
Does something look wrong? Fix it. | View contact records from MINK THERAPEUTICS
MiNK Therapeutics Org Chart and Mapping
Email
Phone
Similar Companies to MiNK Therapeutics
Agenus
-
201-500
-
$ 250 Million to 500 Million
Allogene Therapeutics
-
201-500
-
$ 1 Million to 5 Million
Apellis Pharmaceuticals
-
501-1000
-
$ 50 Million to 100 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding MiNK Therapeutics
Answer: MiNK Therapeutics's headquarters are located at 3 Forbes Rd, Lexington, , 2421, Massachusetts, United States
Answer: MiNK Therapeutics's phone number is 21********
Answer: MiNK Therapeutics's official website is https://minktherapeutics.com
Answer: MiNK Therapeutics's revenue is $5 Million to $10 Million
Answer: MiNK Therapeutics's SIC: 2836
Answer: MiNK Therapeutics's NAICS: 325414
Answer: MiNK Therapeutics has 11-50 employees
Answer: MiNK Therapeutics is in Biotechnology
Answer: MiNK Therapeutics top competitors include: Agenus , Allogene Therapeutics , Apellis Pharmaceuticals
Answer: MiNK Therapeutics contact info: Phone number: 21******** Website: https://minktherapeutics.com
Answer: We are a clinical stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer (NK) cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease (GvHD). Our proprietary platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. As such, we believe that our approach represents a highly versatile application for therapeutic development in cancer and immune diseases. We have leveraged our platform and manufacturing capabilities to develop a wholly owned pipeline for both native and engineered iNKT cells.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month